In a little noticed move, the company that sells the Addyi pill for female sexual dysfunction recently won regulatory approval in Canada, thanks to a followup study designed to address a nagging safety question. But while the endorsement may set the stage for a commercial revival in the U.S., where the drug has been a spectacular flop, it’s not clear the findings will put the safety concerns to rest.

At issue is the extent to which women should drink alcohol while on the drug, since it must be taken every day to be effective. In fact, when it was first approved nearly three years ago by the U.S. Food and Drug Administration, the product labeling warned that alcohol and Addyi should not be taken together. But in approving Addyi, Health Canada decided only to place limits on that interaction.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • It seems that every member of the chief medical adviser’s office is female – along with, possibly, the chief adviser as well. Purely a coincidence, I am sure.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy